Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01715818 · ClinicalTrials.gov registry record · Phase 3
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,999
- Enrollment target
NCT01715818 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 1,999 participants.
The verdict
NCT01715818, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,999 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled, parallel group, multicenter study will evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose abnormalities. Patients will be randomized 1:1 to receive either aleglitazar 150 mcg orally daily or matching placebo.
Interventions
- DRUG Placebo
- DRUG aleglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,999 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01715818
The ClinicalTrials.gov registry entry for NCT01715818 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,999 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01715818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01715818 about?
NCT01715818 is a clinical study titled "A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities". This randomized, double-blind, placebo-controlled, parallel group, multicenter study will evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose abnormalities. Patients will be randomized 1:1 to receive either aleglitazar 150 mc...
What is the current status of trial NCT01715818?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,999 participants. The study started on 2012-12. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01715818?
The interventions under investigation include: Placebo (DRUG), aleglitazar (DRUG).
Who is sponsoring clinical trial NCT01715818?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.